H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Tempest Therapeutics to $47 from $35 and keeps a Buy rating on the shares. The company this morning announced an “impressive update” by Roche’s MORPHEUS-Liver study, specifically the Phase 1b/2 randomized portion comparing the current first-line standard of care regimen of atezolizumab and bevacizumab +/- TPST-1120, the analyst tells investors in a research note. The firm believes the data position Tempest strongly to “add quite meaningful” to the standard of care regiment in first-line hepatocellular carcinoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TPST:
- Tempest Therapeutics (NASDAQ:TPST) Explodes 2,100% Higher on New Data Release
- Tempest Therapeutics sees needing ‘north of $100M’ to develop drug on its own
- Tempest Therapeutics adopts limited duration stockholder rights plan
- Tempest reports results from data analysis of Phase 1b/2 study of TPST-1120
- Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
